AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Acylpyruvase FAHD1, mitochondrial

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q6P587

UPID:

FAHD1_HUMAN

Alternative names:

Fumarylacetoacetate hydrolase domain-containing protein 1; Oxaloacetate decarboxylase; YisK-like protein

Alternative UPACC:

Q6P587; B1AK40; B1AK41; Q6FIC7; Q96RY1; Q9H0N6

Background:

Acylpyruvase FAHD1, a mitochondrial protein, exhibits a unique enzymatic profile, hydrolyzing acetylpyruvate and fumarylpyruvate, as evidenced by studies (PubMed:15551868, PubMed:21878618). Additionally, it possesses oxaloacetate decarboxylase activity, contributing to its multifunctional role in cellular metabolism (PubMed:25575590). Known alternatively as Fumarylacetoacetate hydrolase domain-containing protein 1, Oxaloacetate decarboxylase, and YisK-like protein, FAHD1's biochemical versatility underscores its significance in metabolic pathways.

Therapeutic significance:

Understanding the role of Acylpyruvase FAHD1 could open doors to potential therapeutic strategies, offering new avenues for drug discovery and development. Its involvement in key metabolic processes highlights its potential as a target for therapeutic intervention.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.